$4.38
0.00% today
Nasdaq, Jul 14, 07:17 pm CET
ISIN
US8106481059
Symbol
SCPH
Sector
Industry

scPharmaceuticals, Inc. Stock price

$4.38
+0.30 7.35% 1M
+0.87 24.79% 6M
+0.84 23.73% YTD
-0.22 4.78% 1Y
-0.88 16.73% 3Y
-2.94 40.16% 5Y
-9.72 68.94% 10Y
-9.72 68.94% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.09 2.01%
ISIN
US8106481059
Symbol
SCPH
Sector
Industry

Key metrics

Basic
Market capitalization
$231.2m
Enterprise Value
$224.7m
Net debt
positive
Cash
$57.5m
Shares outstanding
50.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.5 | 3.0
EV/Sales
5.4 | 3.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
12.4%
Return on Equity
-639.3%
ROCE
-106.8%
ROIC
-
Debt/Equity
-10.0
Financials (TTM | estimate)
Revenue
$42.0m | $75.9m
EBITDA
$-79.6m | $-48.6m
EBIT
$-79.7m | $-53.7m
Net Income
$-90.8m | $-53.6m
Free Cash Flow
$-70.0m
Growth (TTM | estimate)
Revenue
138.0% | 109.0%
EBITDA
-33.4% | 24.9%
EBIT
-33.5% | 17.1%
Net Income
-57.3% | 37.1%
Free Cash Flow
-15.8%
Margin (TTM | estimate)
Gross
68.9%
EBITDA
-189.5% | -64.0%
EBIT
-189.9%
Net
-216.2% | -70.6%
Free Cash Flow
-166.7%
More
EPS
$-1.7
FCF per Share
$-1.4
Short interest
3.9%
Employees
163
Rev per Employee
$220.0k
Show more

Is scPharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

scPharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a scPharmaceuticals, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a scPharmaceuticals, Inc. forecast:

Buy
91%
Hold
9%

Financial data from scPharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
42 42
138% 138%
100%
- Direct Costs 13 13
162% 162%
31%
29 29
129% 129%
69%
- Selling and Administrative Expenses 82 82
36% 36%
194%
- Research and Development Expense 14 14
13% 13%
33%
-80 -80
33% 33%
-189%
- Depreciation and Amortization 0.16 0.16
129% 129%
0%
EBIT (Operating Income) EBIT -80 -80
34% 34%
-190%
Net Profit -91 -91
57% 57%
-216%

In millions USD.

Don't miss a Thing! We will send you all news about scPharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

scPharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
about 2 months ago
Shares of scPharmaceuticals have lost 37% over the past 3 years and are down 11% in 2025. Furoscix's subcutaneous administration offers the potential to keep heart failure patients at home longer and cut down on hospital readmissions. Q1 seasonality is in the rearview mirror, with multiple tailwinds, including Medicare redesign and label expansion, to fuel growth going forward.
Neutral
Seeking Alpha
2 months ago
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants William Thorpe - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H.C. Wainwright Chas...
Neutral
GlobeNewsWire
2 months ago
Generated net FUROSCIX ® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and ...
More scPharmaceuticals, Inc. News

Company Profile

scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Head office United States
CEO John Tucker
Employees 163
Founded 2013
Website www.scpharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today